Advertisement

Topics

Navitor Pharmaceuticals to Develop NV-5138, a Specific Activator of mTORC1 for Treatment-Resistant Depression, Based on Promising Data Presented at Society for Neuroscience 2017

07:00 EST 15 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
First data on NV-5138 demonstrating direct mTORC1 activation resulting in ketamine-like rapid antidepressant effects in preclinical animal models Navitor unveils first therapeutic resulting from its mTORC1 drug d...

Other Sources for this Article

The Yates Network
Kathryn Morris, 914-204-6412
kathryn@theyatesnetwork.com

NEXT ARTICLE

More From BioPortfolio on "Navitor Pharmaceuticals to Develop NV-5138, a Specific Activator of mTORC1 for Treatment-Resistant Depression, Based on Promising Data Presented at Society for Neuroscience 2017"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...